✦ LIBER ✦

677 - TAXOL® (paclitaxel) 1-hour infusion plus doxorubicin as first line treatment for metastatic breast cancer (MBC) patients

✍ Scribed by E. Mickiewicz; M. Di Noto; C. Bas; M. Ventnglia; S. Jovtis; D. Lewi; M. Rondinón; G. Temperley; M. Trigo; A. Bertoncin; M.E. Pascual; G. Uranga; E. Cazap; S. Breier; S. Grasso; R. Estévez; G. Rubio; A.M. Alvarez

Book ID: 117664924
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 244 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)85265-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Paclitaxel plus doxorubicin as first-lin

Paclitaxel plus doxorubicin as first-line treatment for breast cancer?

✍ Innes, Carmen 📂 Article 📅 1999 🏛 Adis International Limited (now part of Wolters Kl ⚖ 845 KB

354 Taxol® (paclitaxel) 225 MG/M2 by 3-h

354 Taxol® (paclitaxel) 225 MG/M2 by 3-hour infusion without G-CSF as a first line therapy in patients with metastatic breast cancer (MBC)

✍ J. Bonneterre; M. Tubiana-Hulm; Ph. Chollet; B. Chevallier; P. Fumoleau; P. Kerb 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Lapatinib plus paclitaxel versus paclita

Lapatinib plus paclitaxel versus paclitaxel alone for first line metastatic breast cancer (MBC) in ErbB2+ patients -Quality of Life (QOL) results

✍ Y. Wu; A. Segreti; D. Cella; A. DiLeo; M. Amonkar; M. Koehler; M. Arbushites; M. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB

378 Taxol® (paclitaxel) 225 mg/m2 b

378 Taxol® (paclitaxel) 225 mg/m2 by 3-hour infusion without G-CSF as a second line therapy in patients (PTS) with metastatic breast cancer (MBC)

✍ Ph. Bougnoux; R. Delva; D. Serin; M. Namer; G. Piot; J.P. Lotz; J.F. Ramée; E. V 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Randomized open-label phase III multicen

Randomized open-label phase III multicenter trial comparing TAXOL®/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer

✍ Płuż;zańska, A.; Jassem, J.; Jelič, S.; Gorbunova, V.; Mrsič-Krmpotič, Z.; Berzi 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 152 KB

Capecitabine plus paclitaxel versus epir

Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group

✍ Hans-Joachim Lück, Andreas Du Bois, Sibylle Loibl, Iris Schrader, Jens Huober, V 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 279 KB